Fiduciary Trust’s Pliant Therapeutics PLRX Stock Holding History

Fiduciary Trust’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.2K	Hold	11,620	–	–	﹤0.01%	892
2026 Q1	$14.6K	Hold	11,620	–	–	﹤0.01%	865
2025 Q4	$14.2K	Hold	11,620	–	–	﹤0.01%	857
2025 Q3	$17.2K	Hold	11,620	–	–	﹤0.01%	846
2025 Q2	$13.5K	Hold	11,620	–	–	﹤0.01%	827
2025 Q1	$15.7K	Hold	11,620	–	–	﹤0.01%	816
2024 Q4	$153K	Hold	11,620	–	–	﹤0.01%	672
2024 Q3	$130K	Hold	11,620	–	–	﹤0.01%	643
2024 Q2	$125K	Hold	11,620	–	–	﹤0.01%	615
2024 Q1	$173K	Hold	11,620	–	–	﹤0.01%	625
2023 Q4	$210K	Hold	11,620	–	–	﹤0.01%	599
2023 Q3	$201K	Hold	11,620	–	–	﹤0.01%	592
2023 Q2	$211K	Buy	11,620 +3,620	+45%	+$85.7K	﹤0.01%	600
2023 Q1	$213K	Sell	8,000 -2,711	-25%	-$77.2K	﹤0.01%	588
2022 Q4	$207K	Buy	+10,711	New	+$224K	﹤0.01%	597

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Fiduciary Trust's PLRX Position: Q2 2026 in Review

Fiduciary Trust held its Pliant Therapeutics (PLRX) position steady in Q2 2026 at 11,620 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #892.

Fiduciary Trust first reported a position in PLRX in Q4 2022 and has held it in 15 quarters since. The position peaked at $213K in Q1 2023. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Fiduciary Trust held 11,620 shares of Pliant Therapeutics worth $13.2K as of Q2 2026.
Fiduciary Trust left its Pliant Therapeutics share count unchanged in Q2 2026.
Pliant Therapeutics made up ﹤0.01% of Fiduciary Trust's portfolio in Q2 2026, its #892 holding.
Fiduciary Trust first reported a position in Pliant Therapeutics in Q4 2022 and has held it in 15 quarters since.
Fiduciary Trust's Pliant Therapeutics position peaked at $213K in Q1 2023.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.